In addition, the authors demonstrate that ivacaftor decreases stemness marker gene expressions of GSCs, including CD133, CD44, and Sox2. In summary, the findings reveal that ivacaftor inhibits glioblastoma progression via specifically eliminating GSCs, which opens a new avenue for GBM clinical therapy in the future.
Countstar Connection
The research obtained flow-cytometry measurements from the study's cell samples using a Countstar instrument during growth assessment for the cancer-model experiments.
